Cipla has introduced Cippoint, a point-of-care testing device in Mumbai. It offers testing for things like coagulation markers, thyroid function, metabolic markers, diabetes, infectious diseases, and cardiac markers.
The device has CE IVD approval. According to the company, this indicates that it has received approval from the European In-Vitro Diagnostic Device Directive, ensuring accurate testing procedures. With the entry into these new markets, Cipla has increased the range of products it offers to diagnostics laboratories. Cipla hopes to close the current gap in India’s diagnostic ecosystem by supplying reliable, accurate tests at reasonable costs.
A faster clinical decision-making process will be possible due to Cippoint, an immunofluorescence-based quantitative analyser that gives healthcare providers access to test results in 3–15 minutes. Cippoint offers an automated system and a user-friendly interface that can be used even in remote locations with weak infrastructure, mobile vans, and rural areas.
Achin Gupta, CEO of One India Business at Cipla, commented on the launch by saying, “Cipla has always been at the forefront of addressing the global diseases burden. We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum.”